MBX Biosciences, Inc.

MBX Healthcare Biotechnology

EPS
−34.5%
Free cash flow
−29.7%

Quarter to June 2026, against a year earlier

51.27 2.81 +5.80%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(24.43%) (27.76%) (25.73%) (33.17%)
ROA
(23.59%) (26.61%) (24.79%) (31.25%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(20.78%) (23.58%) (19.81%) (25.51%)
Free Cash Flow per Share
(2.31) (2.24) (1.71) (1.79)
Free Cash Flow
(78.91) (81.88) (79.81) (85.20)
Other line items

Show all line items

Columns are period end dates